Tag
•
Remember that examination of Wyeth (now Pfizer)’s ghostwriting practices that ran in PLoS Medicine a few weeks back? Well, Pharmalot’s…

•
Writing in PLoS Medicine, Adriane J. Fugh-Berman, M.D., demonstrates the cynical art of “publication planning” and the use of academic…

•
Medtronic is back at the FDA, asking for approval of another spine fusion product. Not coincidentally, the Journal Sentinel‘s John…

•
Over at Pharmalot, Covering Health veteran Ed Silverman reports on one European activist group’s survey of corporate sponsorship and disclosure…

•
PZ Myers of the Pharyngula blog on ScienceBlogs reports that Seed CEO and editor-in-chief Adam Bly has sent a letter…

•
John Fauber of the Milwaukee Journal Sentinel reports on outside authors of drug company-funded studies who do not have access…

•
Crikey.com, a news Web site based in Melbourne, Australia, calls our attention to some recent reporting about Mabthera, a drug…

•
Sen. Chuck Grassley, the prolific writer of public letters who often assumes the mantle of health consumer advocate, is at…

A Syracuse University professor charged with reforming health insurance reimbursements gave up her position on an insurance company’s board on…

•
Harvard doctors will now be limited to making $5,000 a year for serving as board members for drugmakers and biotech…
